Lifeline Skin Care, Inc, a wholly owned subsidiary of International Stem
Cell Corporation (OTCBB:ISCO),
www.internationalstemcell.com,
announced today that it has retained the services of a highly
experienced expert in the skin care industry, Raulee Marcus, to help
design a marketing program for its newly created line of skin care
products based on ISCO's proprietary Parthenogenic Stem Cells.
Ms. Marcus has an extensive background in skin care products, having
been a key corporate executive with responsibilities for marketing, R&D
and sales at companies such as Neutrogena, Colgate-Palmolive and
Gillette, increasing sales at those companies by many millions of
dollars. She has also had a highly successful career in building
revenues and profits for smaller companies such as Obagi Medical
Products, a physician-mediated company, and has extensive experience in
launching new brands and products through many different channels.
"Ms. Marcus is uniquely qualified to help us develop a product strategy
that will have maximum market impact for what is truly a unique
technology," said Dr. Ruslan Semechkine, President of Lifeline Skin Care.
"Ms. Marcus' experience in the skin care industry and as a consultant to
companies in that industry will greatly enhance our ability to develop a
successful marketing and business strategy without distracting from our
core focus on developing therapeutic products from Parthenogenic Stem
Cells," said Kenneth Aldrich, Chairman of ISCO.
"Early indications are that the skin care product, developed through the
efforts of the ISCO scientists who created Parthenogenic Stem Cells, has
unique characteristics for skin rejuvenation. Our next step is to
validate these findings through independent testing and execute our
product launch," said Dr. Semechkine.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists have created the first Parthenogenetic homozygous stem
cell line (phSC-Hhom-4) that can be a source of therapeutic cells
that will minimize immune rejection after transplantation into hundreds
of millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com or Brian
Lundstrom, President 760-640-6383 bl@intlstemcell.com or The
Investor Relations Group 212-825-3210 Media Relations: Laura
Colontrelle lcolontrelle@investorrelationsgroup.com or Investor
Relations: James Carbonara jcarbonara@investorrelationsgroup.com |